Get the Stockscreener App
0.8201
4.64%
-0.0399
After Hours:
.81
-0.0101
-1.23%
Citius Pharmaceuticals Inc stock is traded at $0.8201, with a volume of 169.39K.
It is down -4.64% in the last 24 hours and down -46.05% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$0.86
Open:
$0.899
24h Volume:
169.39K
Relative Volume:
0.59
Market Cap:
$9.36M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.1374
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
-17.99%
1M Performance:
-46.05%
6M Performance:
-91.11%
1Y Performance:
-95.53%
1-Day Range:
$0.81
$0.90
1-Week Range:
$0.8086
$1.0118
52-Week Range:
$0.8086
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.8201 | 9.36M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Citius Pharmaceuticals stock hits 52-week low at $0.92 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals (CTXR) Price Target Adjusted to $4 Amid S - GuruFocus
Citius Pharmaceuticals stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.94 - Investing.com Australia
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Pharmaceuticals stock hits 52-week low at $1.21 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $1.21 By Investing.com - Investing.com India
Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock - MSN
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com Australia
Citius Pharmaceuticals announces $2M registered direct offering of common stock - TipRanks
IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter
Analysts Expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) To Breakeven Soon - simplywall.st
Citius Pharmaceuticals stock hits 52-week low at $1.45 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $1.45 - Investing.com India
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - simplywall.st
Fisher Asset Management LLC Acquires Shares of 12,800 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharma Advances LYMPHIR Launch Amid Financial Updates - TipRanks
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at D. Boral Capital - Defense World
Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN
Citius Pharmaceuticals stock hits 52-week low at $2.43 By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals stock hits 52-week low at $2.43 - Investing.com India
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology Inc. (CTOR) reports earnings - Quartz
Citius Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - Financial Times
Citius Pharmaceuticals (CTXR) Projected to Post Quarterly Earnings on Wednesday - Defense World
Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World
Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria
Dr Reddy's Signed Agreement With Citius Pharma To Sell Anti-Cancer Drug - BW Healthcare World
Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6% - Defense World
Citius Pharmaceuticals (STU:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals Completes Registered Direct Offering, Raises $2.7 MillionOn January 7, 2025, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced the closure of a securities purchase agreement with certain institutional investors for a regist - Defense World
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):